Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.76 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.76 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313416 | 0.94 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL4314842 | 0.91 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL4314454 | 0.91 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL21579857 | 0.89 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL1616712 | 0.87 | TLR7 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL29421427 | 0.87 | TLR7 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL29421426 | 0.87 | TLR7 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL20199817 | 0.87 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL2743940 | 0.86 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| Water SCHEMBL4531043 | 0.86 | TLR7 (0.72) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| EP-4419112-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | Ohio State Innovation Foundation (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118475357-A | Immunotherapy for the treatment of cancer | 俄亥俄州创新基金会 | 2024-08-09 | — | — | CN | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20200345842-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-05 | — | — | US | disclosed |
| US-10722573-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-07-28 | — | — | US | disclosed |
| US-8883174-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120082700-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-04-05 | — | — | US | disclosed |
| EP-2411521-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | The Board of Regents of The University of Texas System (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111485-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1850849-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | Coley Pharmaceutical Group, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | TLR7 194/4885TLR8 494/4885NUDT1 302/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | TLR7 55/4885TLR8 236/4885NUDT1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.